JP2010529196A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529196A5
JP2010529196A5 JP2010512186A JP2010512186A JP2010529196A5 JP 2010529196 A5 JP2010529196 A5 JP 2010529196A5 JP 2010512186 A JP2010512186 A JP 2010512186A JP 2010512186 A JP2010512186 A JP 2010512186A JP 2010529196 A5 JP2010529196 A5 JP 2010529196A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
deuterium
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010512186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529196A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/007331 external-priority patent/WO2008156632A1/en
Publication of JP2010529196A publication Critical patent/JP2010529196A/ja
Publication of JP2010529196A5 publication Critical patent/JP2010529196A5/ja
Pending legal-status Critical Current

Links

JP2010512186A 2007-06-12 2008-06-12 アザペプチド誘導体 Pending JP2010529196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US6762708P 2008-02-29 2008-02-29
PCT/US2008/007331 WO2008156632A1 (en) 2007-06-12 2008-06-12 Azapeptide derivatives

Publications (2)

Publication Number Publication Date
JP2010529196A JP2010529196A (ja) 2010-08-26
JP2010529196A5 true JP2010529196A5 (OSRAM) 2011-08-04

Family

ID=39730784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512186A Pending JP2010529196A (ja) 2007-06-12 2008-06-12 アザペプチド誘導体

Country Status (25)

Country Link
US (4) US20090036357A1 (OSRAM)
EP (3) EP2003120B9 (OSRAM)
JP (1) JP2010529196A (OSRAM)
KR (2) KR101185899B1 (OSRAM)
CN (2) CN102424668A (OSRAM)
AR (1) AR066972A1 (OSRAM)
AT (2) ATE447554T1 (OSRAM)
AU (1) AU2008267048C1 (OSRAM)
BR (2) BRPI0823520A2 (OSRAM)
CA (1) CA2692028C (OSRAM)
CO (1) CO6241121A2 (OSRAM)
CY (1) CY1109766T1 (OSRAM)
DE (1) DE602008000255D1 (OSRAM)
DK (1) DK2003120T3 (OSRAM)
ES (3) ES2395137T3 (OSRAM)
HR (1) HRP20100065T1 (OSRAM)
MX (1) MX2009013565A (OSRAM)
PL (1) PL2003120T3 (OSRAM)
PT (1) PT2003120E (OSRAM)
RS (1) RS51226B (OSRAM)
RU (2) RU2448958C2 (OSRAM)
SI (1) SI2003120T1 (OSRAM)
TW (1) TW200908970A (OSRAM)
WO (1) WO2008156632A1 (OSRAM)
ZA (1) ZA200909079B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200835693A (en) * 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
BRPI0823520A2 (pt) * 2007-06-12 2013-12-17 Concert Pharmaceuticals Inc Composto derivado de azapeptídeos e composição farmacêutica contendo o mesmo
US9163067B2 (en) * 2008-10-06 2015-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd HIV-1 integrase derived stimulatory peptides interfering with integrase—Rev protein binding
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
MX2012007210A (es) * 2009-12-21 2012-07-23 Janssen R & D Ireland Implante removible degradable para la liberacion sostenida de un compuesto activo.
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
KR101939546B1 (ko) 2011-06-20 2019-01-16 하. 룬드벡 아크티에셀스카브 정신 분열증의 치료를 위한 중수소화 1-피페라지노-3-페닐 인단
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-(2-吡啶基)苄基]-肼羧酸叔丁酯的制备方法
US10603282B2 (en) * 2015-12-02 2020-03-31 Merck Sharp & Dohme Corp. Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
EP4321513A3 (en) 2016-03-28 2024-05-08 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
AU2018342471B2 (en) 2017-09-27 2023-08-24 Incyte Corporation Salts of pyrrolotriazine derivatives useful as TAM inhibitors
DK3813800T3 (da) 2018-06-29 2025-06-02 Incyte Corp Formuleringer af en axl/mer-hæmmer
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
JP2023522210A (ja) * 2020-04-16 2023-05-29 ザ メディカル カレッジ オブ ウィスコンシン インク 気道逆流の治療のためのhivプロテアーゼ阻害剤のエアロゾル化製剤
CN115385983A (zh) * 2022-01-11 2022-11-25 嘉兴安谛康生物科技有限公司 氮杂双环类化合物及其制备方法、药物组合物和用途
AU2024283382A1 (en) 2023-05-31 2025-11-13 Gilead Sciences, Inc. Anti-hiv compounds

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT82580B (pt) 1985-05-15 1989-01-17 Wellcome Found Processo para a preparacao de 2',3'- didesoxinucleosidos e de composicoes farmaceuticas que os contem
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
EP0727419B1 (en) 1992-12-29 2002-02-27 Abbott Laboratories Intermediates for the preparation of retroviral protease inhibiting compounds
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
ATE372966T1 (de) 1994-03-25 2007-09-15 Isotechnika Inc Verbesserung der effektivität von arzneimitteln duren deuterierung
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
WO1997046514A1 (en) 1996-05-31 1997-12-11 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
EP1390063B1 (en) 2001-05-03 2004-11-17 F. Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
YU12204A (sh) 2001-08-31 2006-08-17 Bristol Myers Squibb Company Korišćenje atazanavira u terapiji hiv-a
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
AU2004273773B2 (en) 2003-02-21 2008-01-24 Jarrow Formulas, Inc. Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
AU2005270124B2 (en) * 2004-07-06 2011-09-08 Abbvie Inc. Prodrugs of HIV protease inhibitors
KR20070083839A (ko) 2004-09-29 2007-08-24 코디스 코포레이션 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태
CA2588466A1 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
MX2009002398A (es) * 2006-09-05 2009-03-16 Schering Corp Combinaciones farmaceuticas para manejo de lipidos y en el tratamiento de aterosclerosis y estatosis hepatica.
BRPI0823520A2 (pt) * 2007-06-12 2013-12-17 Concert Pharmaceuticals Inc Composto derivado de azapeptídeos e composição farmacêutica contendo o mesmo
US20090076097A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Similar Documents

Publication Publication Date Title
JP2010529196A5 (OSRAM)
JP2012111758A5 (OSRAM)
JP2011510079A5 (OSRAM)
JP2012107057A5 (OSRAM)
JP2006515626A5 (OSRAM)
JP2009535462A5 (OSRAM)
JP2007269812A5 (OSRAM)
JP2013532130A5 (OSRAM)
JP2009545527A5 (OSRAM)
JP2011105738A5 (OSRAM)
JP2011508438A5 (OSRAM)
JP2010019854A5 (OSRAM)
JP2013500371A5 (OSRAM)
JP2012514009A5 (OSRAM)
JP2013173782A5 (OSRAM)
JP2009013167A5 (ja) 有機金属錯体、発光材料、発光素子、及び発光装置
JP2011519871A5 (OSRAM)
JP2008188757A5 (OSRAM)
JP2011037885A5 (OSRAM)
JP2009506999A5 (OSRAM)
JP2010241791A5 (OSRAM)
JP2009249685A5 (OSRAM)
JP2006518752A5 (OSRAM)
JP2006305390A5 (OSRAM)
JP2011515327A5 (OSRAM)